Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

"Most viewed" articles are from the articles published during the last six months

Snapshot

Examining the therapeutic landscape of beta-blockers in portal hypertension

Anna Brujats, Càndid Villanueva

Clin Mol Hepatol. 2024;30(4):1055-1059. Published online March 6, 2024

DOI: https://doi.org/10.3350/cmh.2024.0144

View: 5659 Download: 58

Review

MAFLD: How is it different from NAFLD?

Cameron Gofton, Yadhavan Upendran, Ming-Hua Zheng, Jacob George

Clin Mol Hepatol. 2023;29(Suppl):S17-S31. Published online November 29, 2022

DOI: https://doi.org/10.3350/cmh.2022.0367

View: 18502 Download: 1,309 Web of Science: 119 Crossref: 137

Original Article

Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma

Yee Hui Yeo, Jamil S. Samaan, Wee Han Ng, Peng-Sheng Ting, Hirsh Trivedi, Aarshi Vipani, Walid Ayoub, Ju Dong Yang, Omer Liran, Brennan Spiegel, Alexander Kuo

Clin Mol Hepatol. 2023;29(3):721-732. Published online March 22, 2023

DOI: https://doi.org/10.3350/cmh.2023.0089

View: 20952 Download: 1,585 Web of Science: 231 Crossref: 248

Review

Global incidence and prevalence of nonalcoholic fatty liver disease

Margaret LP Teng, Cheng Han Ng, Daniel Q. Huang, Kai En Chan, Darren JH Tan, Wen Hui Lim, Ju Dong Yang, Eunice Tan, Mark D. Muthiah

Clin Mol Hepatol. 2023;29(Suppl):S32-S42. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0365

View: 14579 Download: 566 Web of Science: 163 Crossref: 198

Guideline

2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea

Clin Mol Hepatol. 2022;28(4):583-705. Published online October 1, 2022

DOI: https://doi.org/10.3350/cmh.2022.0294

View: 15973 Download: 784 Web of Science: 134 Crossref: 145

Original Article

Gut microbiome and metabolome signatures in liver cirrhosis-related complications

Satya Priya Sharma, Haripriya Gupta, Goo-Hyun Kwon, Sang Yoon Lee, Seol Hee Song, Jeoung Su Kim, Jeong Ha Park, Min Ju Kim, Dong-Hoon Yang, Hyunjoon Park, Sung-Min Won, Jin-Ju Jeong, Ki-Kwang Oh, Jung A Eom, Kyeong Jin Lee, Sang Jun Yoon, Young Lim Ham, Gwang Ho Baik, Dong Joon Kim, Ki Tae Suk

Clin Mol Hepatol. 2024;30(4):845-862. Published online July 25, 2024

DOI: https://doi.org/10.3350/cmh.2024.0349

View: 3596 Download: 928 Crossref: 2

Review

Liver sinusoidal endothelial cell: An important yet often overlooked player in the liver fibrosis

Jiaorong Qu, Le Wang, Yufei Li, Xiaojiaoyang Li

Clin Mol Hepatol. 2024;30(3):303-325. Published online February 28, 2024

DOI: https://doi.org/10.3350/cmh.2024.0022

View: 4323 Download: 293 Web of Science: 3 Crossref: 4

Original Article

Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis

Harry Crane, Guy D. Eslick, Cameron Gofton, Anjiya Shaikh, George Cholankeril, Mark Cheah, Jian-Hong Zhong, Gianluca Svegliati-Baroni, Alessandro Vitale, Beom Kyung Kim, Sang Hoon Ahn, Mi Na Kim, Simone I Strasser, Jacob George

Clin Mol Hepatol. 2024;30(3):436-448. Published online April 16, 2024

DOI: https://doi.org/10.3350/cmh.2024.0109

View: 4172 Download: 273 Web of Science: 7 Crossref: 9

Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic liver disease

Yiyuan Zheng, Lina Zhao, Zhekun Xiong, Chaoyuan Huang, Qiuhong Yong, Dan Fang, Yugang Fu, Simin Gu, Chong Chen, Jiacheng Li, Yingying Zhu, Jing Liu, Fengbin Liu, Yong Li

Clin Mol Hepatol. 2024;30(3):449-467. Published online April 16, 2024

DOI: https://doi.org/10.3350/cmh.2024.0047

View: 4019 Download: 372 Web of Science: 4 Crossref: 4

Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma

Jiwon Hong, Jung Woo Eun, Geum Ok Baek, Jae Youn Cheong, Seryoung Park, Soon Sun Kim, Hyo Jung Cho, Su Bin Lim

Clin Mol Hepatol. 2024;30(3):360-374. Published online March 15, 2024

DOI: https://doi.org/10.3350/cmh.2024.0042

View: 4033 Download: 319 Web of Science: 3 Crossref: 3

Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study

Young Eun Chon, Dong Yun Kim, Mi Na Kim, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Yeonjung Ha, Joo Ho Lee, Kwan Sik Lee, Beodeul Kang, Jung Sun Kim, Hong Jae Chon, Do Young Kim

Clin Mol Hepatol. 2024;30(3):345-359. Published online March 12, 2024

DOI: https://doi.org/10.3350/cmh.2023.0553

View: 3904 Download: 393 Web of Science: 3 Crossref: 4

Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy

Qi Wang, Qingfa Bu, Zibo Xu, Yuan Liang, Jinren Zhou, Yufeng Pan, Haoming Zhou, Ling Lu

Clin Mol Hepatol. 2024;30(3):515-538. Published online May 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0107

View: 3188 Download: 257 Web of Science: 2 Crossref: 2

Snapshot

Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations

Xinyi Lu, Rui Yang, Yu Chen, Daozhen Chen

Clin Mol Hepatol. 2024;30(3):582-584. Published online December 29, 2023

DOI: https://doi.org/10.3350/cmh.2023.0555

View: 7515 Download: 93

Review

Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Kuei-Chuan Lee, Pei-Shan Wu, Han-Chieh Lin

Clin Mol Hepatol. 2023;29(1):77-98. Published online October 13, 2022

DOI: https://doi.org/10.3350/cmh.2022.0237

View: 11921 Download: 735 Web of Science: 63 Crossref: 67

Original Article

Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study

Seogsong Jeong, Yun Hwan Oh, Joseph C Ahn, Seulggie Choi, Sun Jae Park, Hye Jun Kim, Gyeongsil Lee, Joung Sik Son, Heejoon Jang, Dong Hyeon Lee, Meng Sha, Lei Chen, Won Kim, Sang Min Park

Clin Mol Hepatol. 2024;30(3):487-499. Published online May 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0145

View: 2850 Download: 226 Web of Science: 1 Crossref: 1

Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma

Chun-Ting Ho, Elise Chia-Hui Tan, Pei-Chang Lee, Chi-Jen Chu, Yi-Hsiang Huang, Teh-Ia Huo, Yu-Hui Su, Ming-Chih Hou, Jaw-Ching Wu, Chien-Wei Su

Clin Mol Hepatol. 2024;30(3):406-420. Published online April 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0103

View: 3087 Download: 165 Web of Science: 4 Crossref: 4

Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis

Juchul Hwang, Hyeyoung Hwang, Hyunjae Shin, Bo Hyun Kim, Seong Hee Kang, Jeong-Ju Yoo, Mi Young Choi, Dong eun Lee, Dae Won Jun, Yuri Cho

Clin Mol Hepatol. 2024;30(3):561-576. Published online June 3, 2024

DOI: https://doi.org/10.3350/cmh.2023.0384

View: 2662 Download: 140 Web of Science: 1 Crossref: 2

Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Michael H. Le, Yee Hui Yeo, Biyao Zou, Scott Barnet, Linda Henry, Ramsey Cheung, Mindie H. Nguyen

Clin Mol Hepatol. 2022;28(4):841-850. Published online September 19, 2022

DOI: https://doi.org/10.3350/cmh.2022.0239

View: 9084 Download: 275 Web of Science: 103 Crossref: 113

Review

Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication

Chung-Feng Huang, Manar Hijaze Awad, Meital Gal-Tanamy, Ming-Lung Yu

Clin Mol Hepatol. 2024;30(3):326-344. Published online April 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.0155

View: 2708 Download: 152 Web of Science: 4 Crossref: 2

Original Article

Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study

Moon Haeng Hur, Dong Hyeon Lee, Jeong-Hoon Lee, Mi-Sook Kim, Jeayeon Park, Hyunjae Shin, Sung Won Chung, Hee Jin Cho, Min Kyung Park, Heejoon Jang, Yun Bin Lee, Su Jong Yu, Sang Hyub Lee, Yong Jin Jung, Yoon Jun Kim, Jung-Hwan Yoon

Clin Mol Hepatol. 2024;30(3):500-514. Published online May 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0055

View: 2568 Download: 167 Crossref: 1

Review

Current status and perspective on molecular targets and therapeutic intervention strategy in hepatic ischemia-reperfusion injury

Jia Liu, Ranyi Luo, Yinhao Zhang, Xiaojiaoyang Li

Clin Mol Hepatol. 2024;30(4):585-619. Published online July 1, 2024

DOI: https://doi.org/10.3350/cmh.2024.0222

View: 2151 Download: 252

Original Article

Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients

Man-Fung Yuen, Wan-Long Chuang, Cheng-Yuan Peng, Wen-Juei Jeng, Wei-Wen Su, Ting-Tsung Chang, Chi-Yi Chen, Yao-Chun Hsu, Guy De La Rosa, Alaa Ahmad, Ed Luo, Annie L. Conery

Clin Mol Hepatol. 2024;30(3):375-387. Published online March 26, 2024

DOI: https://doi.org/10.3350/cmh.2023.0535

View: 2867 Download: 109 Web of Science: 1 Crossref: 1

Review

Non-alcoholic fatty liver disease: Definition and subtypes

Seul Ki Han, Soon Koo Baik, Moon Young Kim

Clin Mol Hepatol. 2023;29(suppl):S5-S16. Published online December 28, 2022

DOI: https://doi.org/10.3350/cmh.2022.0424

View: 8893 Download: 552 Web of Science: 60 Crossref: 66

Original Article

Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy

Pei-Chien Tsai, Chung-Feng Huang, Ming-Lun Yeh, Meng-Hsuan Hsieh, Hsing-Tao Kuo, Chao-Hung Hung, Kuo-Chih Tseng, Hsueh-Chou Lai, Cheng-Yuan Peng, Jing-Houng Wang, Jyh-Jou Chen, Pei-Lun Lee, Rong-Nan Chien, Chi-Chieh Yang, Gin-Ho Lo, Jia-Horng Kao, Chun-Jen Liu, Chen-Hua Liu, Sheng-Lei Yan, Chun-Yen Lin, Wei-Wen Su, Cheng-Hsin Chu, Chih-Jen Chen, Shui-Yi Tung, Chi‐Ming Tai, Chih-Wen Lin, Ching-Chu Lo, Pin-Nan Cheng, Yen-Cheng Chiu, Chia-Chi Wang, Jin-Shiung Cheng, Wei-Lun Tsai, Han-Chieh Lin, Yi-Hsiang Huang, Chi-Yi Chen, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Chung, Ming-Jong Bair, Ming-Lung Yu, T-COACH Study Group

Clin Mol Hepatol. 2024;30(3):468-486. Published online April 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0038

View: 3101 Download: 177 Web of Science: 3 Crossref: 2

Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction

Mehrangiz Dezhbord, Seong Ho Kim, Soree Park, Da Rae Lee, Nayeon Kim, Juhee Won, Ah Ram Lee, Dong-Sik Kim, Kyun-Hwan Kim

Clin Mol Hepatol. 2024;30(3):539-560. Published online May 14, 2024

DOI: https://doi.org/10.3350/cmh.2024.0060 Correction in: Clin Mol Hepatol 2024;30(4):1060

View: 2905 Download: 245 Web of Science: 5 Crossref: 2

Editorial

The latest global burden of liver cancer: A past and present threat

Joo Hyun Oh, Dae Won Jun

Clin Mol Hepatol. 2023;29(2):355-357. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0070

View: 5542 Download: 127 Web of Science: 40 Crossref: 41

Original Article

Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment

Do Seon Song, Hee Yeon Kim, Young Kul Jung, Tae Hyung Kim, Hyung Joon Yim, Eileen L Yoon, Ki Tae Suk, Jeong-ju Yoo, Sang Gyune Kim, Moon Young Kim, Young Chang, Soung Won Jeong, Jae Young Jang, Sung-Eun Kim, Jung-Hee Kim, Jung Gil Park, Won Kim, Jin Mo Yang, Dong Joon Kim, Korean Acute-on-Chronic Liver Failure (KACLiF) study group, Ashok Kumar Choudhury, Vinod Arora, Shiv Kumar Sarin, APASL ACLF Research Consortium (AARC) for APASL ACLF working party

Clin Mol Hepatol. 2024;30(3):388-405. Published online April 11, 2024

DOI: https://doi.org/10.3350/cmh.2023.0563

View: 2679 Download: 105 Web of Science: 2 Crossref: 2

Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial

Sun Young Yim, Sung Hwan Lee, Seung-Woo Baek, Bohwa Sohn, Yun Seong Jeong, Sang-Hee Kang, Kena Park, Hyewon Park, Sunyoung S. Lee, Ahmed O. Kaseb, Young Nyun Park, Sun-Hee Leem, Michael A. Curran, Ji Hoon Kim, Ju-Seog Lee

Clin Mol Hepatol. 2024;30(4):807-823. Published online July 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0333

View: 1930 Download: 251 Web of Science: 1 Crossref: 2

Review

Immunological mechanisms in steatotic liver diseases: An overview and clinical perspectives

Mengyao Yan, Shuli Man, Long Ma, Lanping Guo, Luqi Huang, Wenyuan Gao

Clin Mol Hepatol. 2024;30(4):620-648. Published online July 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0315

View: 1898 Download: 208 Web of Science: 1 Crossref: 2

Original Article

Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis

Michael H. Le, David M. Le, Thomas C. Baez, Hansen Dang, Vy H. Nguyen, KeeSeok Lee, Christopher D. Stave, Takanori Ito, Yuankai Wu, Yee Hui Yeo, Fanpu Ji, Ramsey Cheung, Mindie H. Nguyen

Clin Mol Hepatol. 2024;30(2):235-246. Published online January 26, 2024

DOI: https://doi.org/10.3350/cmh.2023.0485

View: 5183 Download: 272 Web of Science: 14 Crossref: 16

Viewed By 5060	Examining the therapeutic landscape of beta-blockers in portal hypertension
Viewed By 5025	MAFLD: How is it different from NAFLD?
Viewed By 4466	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4425	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4343	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Cited By 248	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 198	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 145	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 137	MAFLD: How is it different from NAFLD?
Cited By 113	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach